Brought to you by 
Elixir gets rights to targets from MIT, UConn
26 Jul 2002
Executive Summary
Elixir Pharmaceuticals has licensed exclusive rights to patents relating to the aging process from the Massachusetts Institute of Technology and the University of Connecticut.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Elixir gets rights to targets from MIT, UConn
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice